| International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) S Miyakis, MD Lockshin, T Atsumi, DW Branch, RL Brey, R Cervera, ... Journal of thrombosis and haemostasis 4 (2), 295-306, 2006 | 8454 | 2006 |
| Mortality in systemic sclerosis: an international meta-analysis of individual patient data JPA Ioannidis, PG Vlachoyiannopoulos, AB Haidich, TA Medsger Jr, ... The American journal of medicine 118 (1), 2-10, 2005 | 579 | 2005 |
| Mapping and predicting mortality from systemic sclerosis M Elhai, C Meune, M Boubaya, J Avouac, E Hachulla, A Balbir-Gurman, ... Annals of the rheumatic diseases 76 (11), 1897-1905, 2017 | 558 | 2017 |
| Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial D Khanna, CJF Lin, DE Furst, J Goldin, G Kim, M Kuwana, Y Allanore, ... The Lancet Respiratory Medicine 8 (10), 963-974, 2020 | 483 | 2020 |
| Current causes of death in systemic lupus erythematosus in Europe, 2000—2004: relation to disease activity and damage accrual J Nossent, N Cikes, E Kiss, A Marchesoni, V Nassonova, M Mosca, ... Lupus 16 (5), 309-317, 2007 | 327 | 2007 |
| Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: Prevalence, clinical associations, and long‐term outcome MG Tektonidou, F Sotsiou, L Nakopoulou, PG Vlachoyiannopoulos, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 301 | 2004 |
| Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. I Pakas, JPA Ioannidis, K Malagari, FN Skopouli, HM Moutsopoulos, ... The Journal of rheumatology 29 (2), 298-304, 2002 | 216 | 2002 |
| Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19 PG Vlachoyiannopoulos, E Magira, H Alexopoulos, E Jahaj, ... Annals of the Rheumatic Diseases 79 (12), 1661-1663, 2020 | 213 | 2020 |
| European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria G Valentini, W Bencivelli, S Bombardieri, S D’Angelo, A Della Rossa, ... Annals of the rheumatic diseases 62 (9), 901-903, 2003 | 209 | 2003 |
| Subgroups of Sjögren syndrome patients according to serological profiles VK Bournia, PG Vlachoyiannopoulos Journal of autoimmunity 39 (1-2), 15-26, 2012 | 205 | 2012 |
| Presence of systemic autoimmune disorders in patients with autoimmune thyroid diseases MG Tektonidou, M Anapliotou, P Vlachoyiannopoulos, HM Moutsopoulos Annals of the rheumatic diseases 63 (9), 1159-1161, 2004 | 200 | 2004 |
| Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus J Nossent, E Kiss, B Rozman, G Pokorny, P Vlachoyiannopoulos, ... Lupus 19 (8), 949-956, 2010 | 195 | 2010 |
| Digital ulcers predict a worse disease course in patients with systemic sclerosis C Mihai, R Landewé, D Van Der Heijde, UA Walker, PI Constantin, ... Annals of the rheumatic diseases 75 (4), 681-686, 2016 | 181 | 2016 |
| Nailfold videocapillaroscopic features and other clinical risk factors for digital ulcers in systemic sclerosis: a multicenter, prospective cohort study M Cutolo, AL Herrick, O Distler, MO Becker, E Beltran, P Carpentier, ... Arthritis & rheumatology 68 (10), 2527-2539, 2016 | 167 | 2016 |
| Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study J Avouac, UA Walker, E Hachulla, G Riemekasten, G Cuomo, PE Carreira, ... Annals of the rheumatic diseases 75 (1), 103-109, 2016 | 157 | 2016 |
| Asymptomatic avascular necrosis in patients with primary antiphospholipid syndrome in the absence of corticosteroid use: a prospective study by magnetic resonance imaging MG Tektonidou, K Malagari, PG Vlachoyiannopoulos, DA Kelekis, ... Arthritis & Rheumatism 48 (3), 732-736, 2003 | 156 | 2003 |
| Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study PG Vlachoyiannopoulos, PG Kanellopoulos, JPA Ioannidis, ... Rheumatology 42 (5), 645-651, 2003 | 153 | 2003 |
| European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres A Della Rossa, G Valentini, S Bombardieri, W Bencivelli, AJ Silman, ... Annals of the rheumatic diseases 60 (6), 585-591, 2001 | 153 | 2001 |
| Systemic lupus erythematosus: clinical features in patients with a disease duration of over 10 years, first evaluation AJG Swaak, HG van Den Brink, RJT Smeenk, K Manger, JR Kalden, ... Rheumatology 38 (10), 953-958, 1999 | 151 | 1999 |
| Treatment of rheumatoid arthritis: unraveling the conundrum E Zampeli, PG Vlachoyiannopoulos, AG Tzioufas Journal of autoimmunity 65, 1-18, 2015 | 148 | 2015 |
